Literature DB >> 2806827

Long-term prognosis of esophageal variceal cases treated with injection sclerotherapy.

H Miyoshi1, H Tei, K Ashida, N Osaka, A Matsumoto, I Hirata, S Ohshiba.   

Abstract

One hundred fifty-two patients with esophageal varices underwent a total of 485 injection sclerotherapy procedures (mean, 3.2 times per each case). During 5 years of observation, 20 cases (13.2%) died following injection sclerotherapy. The 3-year survival rates, based on the Kaplan-Meier method, were 42% for emergency cases, 75% for elective cases and 90% for prophylactic cases. Significant differences (P less than 0.05) by the generalized Wilcoxon test were observed in the survival rates between emergency cases and prophylactic cases, and also between elective cases and prophylactic cases. Two cases (8.6%) of failure to control acute hemostasis were experienced. Twenty cases of bleeding after sclerotherapy were experienced, and 8 died of bleeding. The three-year bleeding rate according to the Kaplan-Meier method was 59% for emergency cases, 25% for elective cases and 7% for prophylactic cases. A significant difference (P less than 0.05) by the generalized Wilcoxon test was observed in the bleeding rate between elective cases and prophylactic cases. Non-bleeding rate (100%-bleeding rate) after sclerotherapy showed almost the same values as the survival rate. These results indicate that upper digestive tract hemorrhage influences the prognosis of patients after sclerotherapy.

Entities:  

Mesh:

Year:  1989        PMID: 2806827     DOI: 10.1007/bf02773871

Source DB:  PubMed          Journal:  Gastroenterol Jpn        ISSN: 0435-1339


  14 in total

1.  [Endoscopic underspraying for hemostasis in the gastrointestinal tract].

Authors:  N Soehendra; A Knipper
Journal:  Dtsch Med Wochenschr       Date:  1977-11-18       Impact factor: 0.628

2.  Transection of the oesophagus for bleeding oesophageal varices.

Authors:  R N Pugh; I M Murray-Lyon; J L Dawson; M C Pietroni; R Williams
Journal:  Br J Surg       Date:  1973-08       Impact factor: 6.939

3.  Sclerotherapy of esophageal varices--Argentinian experience.

Authors:  A D Jorge; J Adami; L Seiffert; E Segal
Journal:  Endoscopy       Date:  1983-05       Impact factor: 10.093

4.  Injection sclerotherapy of esophageal varices for patients undergoing emergency and elective surgery.

Authors:  Y Takase; A Ozaki; K Orii; K Nagoshi; T Okamura; Y Iwasaki
Journal:  Surgery       Date:  1982-09       Impact factor: 3.982

5.  Influence of hepatic reserve and cause of esophageal varices on survival and rebleeding before and after the introduction of sclerotherapy: a retrospective analysis.

Authors:  E P DiMagno; A R Zinsmeister; D E Larson; T R Viggiano; J E Clain; B L Laughlin; R W Hughes
Journal:  Mayo Clin Proc       Date:  1985-03       Impact factor: 7.616

6.  Failure of repeated injection sclerotherapy to improve long-term survival after oesophageal variceal bleeding. A five-year prospective controlled clinical trial.

Authors:  J Terblanche; P C Bornman; D Kahn; M A Jonker; J A Campbell; J Wright; R Kirsch
Journal:  Lancet       Date:  1983-12-10       Impact factor: 79.321

7.  Endoscopic sclerotherapy v. conservative management of bleeding oesophageal varices. A 5-year prospective controlled trial of emergency and long-term treatment.

Authors:  C Söderlund; T Ihre
Journal:  Acta Chir Scand       Date:  1985

8.  Prophylactic endoscopic sclerotherapy of oesophageal varices. A prospective controlled study.

Authors:  L Witzel; E Wolbergs; H Merki
Journal:  Lancet       Date:  1985-04-06       Impact factor: 79.321

9.  Improved survival following injection sclerotherapy for esophageal varices: final analysis of a controlled trial.

Authors:  D Westaby; B R Macdougall; R Williams
Journal:  Hepatology       Date:  1985 Sep-Oct       Impact factor: 17.425

10.  Prophylactic endoscopic sclerosing treatment of the esophageal wall in varices -- a prospective controlled randomized trial.

Authors:  K J Paquet
Journal:  Endoscopy       Date:  1982-01       Impact factor: 10.093

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.